Actively Recruiting

Phase 1
Age: 18Years - 60Years
All Genders
Healthy Volunteers
NCT06570369

A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression

Led by Sirtsei Pharmaceuticals, Inc. · Updated on 2026-03-02

36

Participants Needed

2

Research Sites

83 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The main goal of this clinical trial is to learn if the active study drug (code name: SP-624) has any effect on the electrical activity of the brain in adult healthy volunteers and in adults with major depression. Another goal of the study is to learn if SP-624 improves memory and learning in adults with major depression. The study will also provide additional information on the safety of SP-624 and how well it is tolerated in adult healthy volunteers and adults with major depression. Researchers will compare SP-624 to a placebo (a look-alike substance that contains no drug) to see if SP-624 has any effect on study tests. Study participants will: Take capsules of study drug (SP-624 or a placebo) once daily for 2 weeks; visit the clinic at Screening, Day 1 (first dose of study drug), and Day 15 (last dose of study drug) for checkups and tests; and have phone call check-ups on Day 7 and about 1 week after the last dose of study drug.

CONDITIONS

Official Title

A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression

Who Can Participate

Age: 18Years - 60Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Be generally in good health
  • Have a body mass index (BMI) between 18.0 and 40.0 kg/m2
  • Be willing to follow the study requirements
  • For participants with depression: have moderate to severe major depressive disorder as defined by the study
Not Eligible

You will not qualify if you...

  • Be a female who is pregnant or breastfeeding
  • Have a clinically significant health condition or abnormal screening test results
  • For participants with depression: have co-morbid psychiatric conditions or medication history that exclude participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

CenExel CNS

Garden Grove, California, United States, 92845

Actively Recruiting

2

Alivation Research

Lincoln, Nebraska, United States, 68526

Completed

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression | DecenTrialz